Aberdeen Group plc Grows Stock Position in Allogene Therapeutics, Inc. $ALLO

Aberdeen Group plc raised its stake in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 31.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 2,086,332 shares of the company’s stock after buying an additional 504,067 shares during the period. Aberdeen Group plc owned about 0.93% of Allogene Therapeutics worth $2,858,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of ALLO. Savant Capital LLC purchased a new position in shares of Allogene Therapeutics in the 3rd quarter valued at about $27,000. Russell Investments Group Ltd. boosted its holdings in shares of Allogene Therapeutics by 11,159.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 21,844 shares of the company’s stock worth $27,000 after purchasing an additional 21,650 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Allogene Therapeutics by 5,267.6% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 24,047 shares of the company’s stock worth $30,000 after purchasing an additional 23,599 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in Allogene Therapeutics in the third quarter valued at approximately $30,000. Finally, Brighton Jones LLC lifted its holdings in Allogene Therapeutics by 81.6% in the third quarter. Brighton Jones LLC now owns 25,168 shares of the company’s stock valued at $31,000 after acquiring an additional 11,311 shares during the last quarter. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Price Performance

NASDAQ:ALLO opened at $2.70 on Thursday. Allogene Therapeutics, Inc. has a 12 month low of $0.86 and a 12 month high of $2.82. The firm has a market capitalization of $658.21 million, a PE ratio of -3.10 and a beta of 0.53. The business’s fifty day moving average price is $2.23 and its 200 day moving average price is $1.67.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.08. As a group, equities analysts anticipate that Allogene Therapeutics, Inc. will post -1.28 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Wall Street Zen upgraded Allogene Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, February 22nd. Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 price objective on shares of Allogene Therapeutics in a research report on Friday, March 13th. Citizens Jmp raised Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a research report on Friday, January 9th. Citigroup raised Allogene Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Friday, January 9th. Finally, Truist Financial raised Allogene Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.56.

Insider Activity at Allogene Therapeutics

In other Allogene Therapeutics news, EVP Zachary Roberts sold 35,700 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $1.77, for a total value of $63,189.00. Following the completion of the transaction, the executive vice president owned 581,166 shares in the company, valued at $1,028,663.82. This represents a 5.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO David D. Chang sold 95,269 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $1.80, for a total transaction of $171,484.20. Following the sale, the chief executive officer owned 5,185,862 shares of the company’s stock, valued at $9,334,551.60. This trade represents a 1.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 278,452 shares of company stock worth $534,053. Insiders own 13.20% of the company’s stock.

About Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.